Evolving health care through personal genomics

Nature Reviews Genetics

Volumn 18, Issue 4, 2017, Pages 259-267

  Rehm, Heidi L ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b LABORATORY FOR MOLECULAR MEDICINE   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL ARTICLE; CLINICAL PRACTICE; CYSTIC FIBROSIS; DECISION MAKING; FEMALE; GENETIC SCREENING; GENOMICS; HEALTH CARE; HEALTH CARE SYSTEM; HEREDITARY TUMOR; HUMAN; HUMAN GENOME; IN VITRO FERTILIZATION; MALE; NEWBORN SCREENING; NEXT GENERATION SEQUENCING; PATIENT CARE; PRIORITY JOURNAL; REVIEW; TAY SACHS DISEASE; WHOLE GENOME SEQUENCING; ADULT; HEALTH CARE DELIVERY; HIGH THROUGHPUT SEQUENCING; PERSONALIZED MEDICINE; PROCEDURES; STANDARDS;

ADULT; DELIVERY OF HEALTH CARE; GENETIC TESTING; GENOME, HUMAN; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; PRECISION MEDICINE;

EID: 85010950574     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg.2016.162     Document Type: Review

References (83)

1. Turakhia, M. P. & Kaiser, D. W. Transforming the care of atrial fibrillation with mobile health. J. Interv. Card. Electrophysiol. 47, 45-50 (2016).
2. Khan, Y., Ostfeld, A. E., Lochner, C. M., Pierre, A. & Arias, A. C. Monitoring of vital signs with flexible and wearable medical devices. Adv. Mater. 28, 4373-4395 (2016).
3. Kolla, B. P., Mansukhani, S. & Mansukhani, M. P. Consumer sleep tracking devices: a review of mechanisms, validity and utility. Expert Rev. Med. Devices 13, 497-506 (2016).
4. Lander, E. S. et al. Initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001).
5. Venter, J. C. et al. The sequence of the human genome. Science 291, 1304-1351 (2001).
6. 1000 Genomes Project Consortium et al. A global reference for human genetic variation. Nature 526, 68-74 (2015).
7. Aronson, S. J. & Rehm, H. L. Building the foundation for genomics in precision medicine. Nature 526, 336-342 (2015).
8. Collins, F. S. & Varmus, H. A new initiative on precision medicine. N. Engl. J. Med. 372, 793-795 (2015).
9. Zhang, B., Dearing, L. & Amos, J. DNA-based carrier screening in the Ashkenazi Jewish population. Expert Rev. Mol. Diagn. 4, 377-392 (2004).
10. American College of Obstetricians and Gynecologists Committee on Genetics. ACOG Committee Opinion No. 486: update on carrier screening for cystic fibrosis. Obstet. Gynecol. 11 7, 1028-1031 (2011).
11. Wedekind, C., Seebeck, T., Bettens, F. & Paepke, A. J. MHC-dependent mate preferences in humans. Proc. Biol. Sci. 260, 245-249 (1995).
12. Fuchs, F. & Riis, P. Antenatal sex determination. Nature 177, 330 (1956).
13. Thung, D. T., Beulen, L., Hehir-Kwa, J. & Faas, B. H. Implementation of whole genome massively parallel sequencing for noninvasive prenatal testing in laboratories. Expert Rev. Mol. Diagn. 15, 111-124 (2015).
14. Lo, J. O., Cori, D. F., Norton, M. E. & Caughey, A. B. Noninvasive prenatal testing. Obstet. Gynecol. Surv. 69, 89-99 (2014).
15. Kitzman, J. O. et al. Noninvasive whole-genome sequencing of a human fetus. Sci. Transl. Med. 4, 137ra76 (2012).
16. Regier, D. S. & Greene, C. I.Phenylalanine hydroxylase deficiency. GeneReviews https://www.ncbi.nlm.nih.gov/books/NBK1504/(updated 20 Oct 2016).
17. Kaback, M. M. Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model. Eur. J. Pediatr. 159 (Suppl. 3), S192-S195 (2000).
18. MacDorman, M. F., Hoyert, D. L. & Mathews, T. J. Recent declines in infant mortality in the United States, 2005-2011. NCHS Data Brief 20, 1-8 (2013).
19. American College of Medical Genetics Newborn Screening Expert Group Newborn Screening: Toward A Uniform Screening Panel and System-executive Summary. Pediatrics 11 7, S296-S307 (2006).
20. Moyer, V. A., Calonge, N., Teutsch, S. M., Botkin, J. R. & United States Preventive Services Task Force. Expanding newborn screening: process, policy, and priorities. Hastings Cent. Rep. 38, 32-39 (2008).
21. Cirino, A. L. & Ho, C. Y. Hypertrophic cardiomyopathy overview. GeneReviews https://www.ncbi.nlm.nih.gov/books/NBK1768/(updated 16 Jan 2014).
22. Lohmann, D. R. & Gallie, B. L. Retinoblastoma. GeneReviews https://www.ncbi.nlm.nih.gov/books/NBK1452/(updated 19 Nov 2015).
23. Kingsmore, S. F. Newborn testing and screening by whole-genome sequencing. Genet. Med. 18, 214-216 (2016).
24. Waisbren, S. E. et al. Parents are interested in newborn genomic testing during the early postpartum period. Genet. Med. 17, 501-504 (2015).
25. Ceyhan-Birsoy, O. et al. A curated gene list for reporting results of newborn genomic sequencing. Genet. Med. http://dx.doi.org/10.1038/gim.2016.193 (2017).
26. Berg, J. S. et al. Newborn sequencing in genomic medicine and public health (NSIGHT). Pediatrics http://dx.doi.org/10.1542/peds.2016-2252 (2017).
27. Lazaridis, K. N. et al. Outcome of whole exome sequencing for diagnostic odyssey cases of an individualized medicine clinic: the Mayo Clinic Experience. Mayo Clin. Proc. 91, 297-307 (2016).
28. Sawyer, S. L. et al. Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care. Clin. Genet. 89, 275-284 (2016).
29. Thevenon, J. et al. Diagnostic odyssey in severe neurodevelopmental disorders: toward clinical whole-exome sequencing as a first-line diagnostic test. Clin. Genet. 89, 700-707 (2016).
30. Might, M. & Might, C. What happens when N = 1 and you want plus 1? Prenat. Diagn. http://dx.doi.org/10.1002/pd.4975 (2016).
31. Alatzoglou, K. S., Webb, E. A., Le Tissier, P. & Dattani, M. T. Isolated growth hormone deficiency (GHD) in childhood and adolescence: recent advances. Endocr. Rev. 35, 376-432 (2014).
32. Forlenza, G. P. et al. Next generation sequencing in endocrine practice. Mol. Genet. Metab. 11 5, 61-71 (2015).
33. Merlo, L. M., Pepper, J. W., Reid, B. J. & Maley, C. C. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 6, 924-935 (2006).
34. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
35. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
36. Rodig, S. J. & Shapiro, G. I. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr. Opin. Investig. Drugs 11, 1477-1490 (2010).
37. Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005).
38. Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684 (2005).
39. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
40. Houillier, C. et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75, 1560-1566 (2010).
41. Lupo, P. J. et al. Patients' perceived utility of whole-genome sequencing for their healthcare: findings from the MedSeq project. Per. Med. 13, 13-20 (2016).
42. Vassy, J. L. et al. The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine. Trials 15, 85 (2014).
43. Meisel, S. F. et al. Explaining, not just predicting, drives interest in personal genomics. Genome Med. 7, 74 (2015).
44. Alfares, A. A. et al. Results of clinical genetic testing of 2, 912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet. Med. 17, 880-888 (2015).
45. Boaretto, F. et al. Diagnosis of primary ciliary dyskinesia by a targeted next-generation sequencing panel: molecular and clinical findings in Italian patients. J. Mol. Diagn. 18, 912-922 (2016).
46. Cizmarova, M. et al. New mutations associated with rasopathies in a Central European population and genotype-phenotype correlations. Ann. Hum. Genet. 80, 50-62 (2016).
47. Lee, H. et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA 312, 1880-1887 (2014).
48. Pugh, T. J. et al. The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. Genet. Med. 16, 601-608 (2014).
49. Schenkel, L. C. et al. Clinical next-generation sequencing pipeline outperforms a combined approach using Sanger sequencing and multiplex ligation-dependent probe amplification in targeted gene panel analysis. J. Mol. Diagn. 18, 657-667 (2016).
50. Shearer, A. E. & Smith, R. J. Massively parallel sequencing for genetic diagnosis of hearing loss: the new standard of care. Otolaryngol. Head Neck Surg. 153, 175-182 (2015).
51. Yang, H. et al. Genetic testing of 248 Chinese aortopathy patients using a panel assay. Sci. Rep. 6, 33002 (2016).
52. Chong, J. X. et al. The genetic basis of Mendelian phenotypes: discoveries, challenges, and opportunities. Am. J. Hum. Genet. 97, 199-215 (2015).
53. Cree, I. A. et al. Guidance for laboratories performing molecular pathology for cancer patients. J. Clin. Pathol. 67, 923-931 (2014).
54. Lindeman, N. I. et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J. Thorac. Oncol. 8, 823-859 (2013).
55. Febbo, P. G. et al. NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. J. Natl Compr. Canc. Netw. 9 (Suppl. 5), S1-S32 (2011).
56. Aradhya, S. et al. Exon-level array CGH in a large clinical cohort demonstrates increased sensitivity of diagnostic testing for Mendelian disorders. Genet. Med. 14, 594-603 (2012).
57. Pugh, T. J. et al. VisCap: inference and visualization of germ-line copy-number variants from targeted clinical sequencing data. Genet. Med. 18, 712-719 (2016).
58. Landrum, M. J. et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 42, D980-D985 (2014).
59. Rehm, H. L. et al. ClinGen-The Clinical Genome Resource. N. Engl. J. Med. 372, 2235-2242 (2015).
60. Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405-424 (2015).
61. Amendola, L. M. et al. Performance of ACMG-AMP variant-interpretation guidelines among nine laboratories in the Clinical Sequencing Exploratory Research Consortium. Am. J. Hum. Genet. 99, 247 (2016).
62. Lek, M. et al. Analysis of protein-coding genetic variation in 60, 706 humans. Nature 536, 285-291 (2016).
63. Amendola, L. M. et al. Actionable exomic incidental findings in 6503 participants: challenges of variant classification. Genome Res. 25, 305-315 (2015).
64. National Center for Biotechnology Information. ClinVar submissions. ClinVar https://www.ncbi.nlm.nih.gov/clinvar/submitters (2016).
65. Philippakis, A. A. et al. The Matchmaker Exchange: a platform for rare disease gene discovery. Hum. Mutat. 36, 915-921 (2015).
66. Thorpe, J. H. & Gray, E. A. Big data and public health: navigating privacy laws to maximize potential. Public Health Rep. 130, 171-175 (2015).
67. Global Alliance for Genomics and Health. A federated ecosystem for sharing genomic, clinical data. Science 352, 1278-1280 (2016).
68. Baker, D. B., Kaye, J. & Terry, S. F. Governance through privacy, fairness, and respect for individuals. EGEMS (Wash. DC) 4, 1207 (2016).
69. Knoppers, B. M. Framework for responsible sharing of genomic and health-related data. HUGO J. 8, 3 (2014).
70. Botkin, J. R. et al. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am. J. Hum. Genet. 97, 6-21 (2015).
71. Botkin, J. R. & Rothwell, E. Whole genome sequencing and newborn screening. Curr. Genet. Med. Rep. 4, 1-6 (2016).
72. Waisbren, S. E., Weipert, C. M., Walsh, R. C., Petty, C. R. & Green, R. C. Psychosocial factors influencing parental interest in genomic sequencing of newborns. Pediatrics 137 (Suppl. 1), S30-S35 (2016).
73. Alders, M. & Christiaans, I. Long QT syndrome. GeneReviews https://www.ncbi.nlm.nih.gov/books/NBK1129/(updated 18 Jun 2015).
74. Charron, P. et al. Penetrance of familial hypertrophic cardiomyopathy. Genet. Couns. 8, 107-114 (1997).
75. Kohlmann, W. & Gruber, S. B. Lynch syndrome. GeneReviews https://www.ncbi.nlm.nih.gov/books/NBK1211/(updated 22 May 2014).
76. Petrucelli, N., Daly, M. B. & Feldman, G. L. BRCA1 and BRCA2 hereditary breast and ovarian cancer. GeneReviews https://www.ncbi.nlm.nih.gov/books/NBK1247/(updated 26 Sep 2013).
77. Whitlock, E. P., Garlitz, B. A., Harris, E. L., Beil, T. L. & Smith, P. R. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 145, 209-223 (2006).
78. Metcalfe, K. et al. Elastin: mutational spectrum in supravalvular aortic stenosis. Eur. J. Hum. Genet. 8, 955-9634 (2000).
79. Deo, S. V. et al. Late outcomes for surgical repair of supravalvar aortic stenosis. Ann. Thorac. Surg. 94, 854-859 (2012).
80. Chong, J. X. et al. Gene discovery for Mendelian conditions via social networking: de novo variants in KDM1A cause developmental delay and distinctive facial features. Genet. Med. 18, 788-795 (2016).
81. Kirkpatrick, B. E. et al. GenomeConnect: matchmaking between patients, clinical laboratories, and researchers to improve genomic knowledge. Hum. Mutat. 36, 974-978 (2015).
82. Lambertson, K. F., Damiani, S. A., Might, M., Shelton, R. & Terry, S. F. Participant-driven matchmaking in the genomic era. Hum. Mutat. 36, 965-973 (2015).
83. Wauters, A. & Van Hoyweghen, I. Global trends on fears and concerns of genetic discrimination: a systematic literature review. J. Hum. Genet. 61, 275-282 (2016).